-
Brian Rini
UrologySUNNIFORECAST: IO-Based Combination and Other Considerations - 30 day(s) agoDear readers, The standard initial treatment for metastatic papillary RCC has recently evolved. Single-agent cabozantinib is a standard based on the PAPMET trial which showed…
-
Brian Rini
UrologyDear readers, Today, I would like to highlight a poll I recently conducted on X. The poll is interesting because there are varied practices regarding…
-
Brian Rini
UrologyNon Clear-Cell RCC: Novel Insights Into the Biology and Treatments - 3 month(s) agoDear readers, I’m Brian Rini, MD, a GU Medical Oncologist at Vanderbilt Ingram Cancer Center. I’m happy to share today a collection of articles related…
-
Brian Rini
UrologyUromigos Live Wrap-Up: RCC and IO-Therapy - 11 month(s) agoDear readers, To wrap up our series on Uromigos Live & Unplugged 2023, I want to highlight a few topics in kidney cancer, particularly renal…
-
Brian Rini
UrologyProminent Data and Discussions from Uromigos Live 2023 - 11 month(s) agoDear readers, Plenty of exciting data came out of Uromigos Live & Unplugged 2023, especially in the renal cell carcinoma (RCC) sphere. I included discussions…
-
Brian Rini
UrologyThe Uromigos Live 2023: Post-Conference Coverage - 11 month(s) agoDear readers, The Uromigos Live and Unplugged meeting wrapped up on November 4 with exciting and thought-provoking discussions. It was a pleasure welcoming everyone to…
-
Brian Rini
UrologyTreatment of Refractory RCC - 2 year(s) agoSeveral datasets have emerged in the refractory RCC space, which is now mostly IO-refractory. Novel targets are needed to make advancements in this challenging population.
-
Brian Rini
UrologyApplication of Systemic Therapy in mRCC - 2 year(s) agoSeveral questions have emerged around metastatic RCC systemic therapy application. Duration of therapy, staggered administration and duration of therapy are all being actively investigated.
-
Brian Rini
UrologyUpdated Front-line RCC Data from ASCO GU 23 - 2 year(s) agoASCO GU 2023 provided some important updates in front-line RCC. The landscape of IO-based doublets continues to evolve.